196 related articles for article (PubMed ID: 35179961)
1. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.
Karantanos T; Teodorescu P; Perkins B; Christodoulou I; Esteb C; Varadhan R; Helmenstine E; Rajkhowa T; Paun BC; Bonifant C; Dalton WB; Gondek LP; Moliterno AR; Levis MJ; Ghiaur G; Jones RJ
Sci Adv; 2022 Feb; 8(7):eabl8952. PubMed ID: 35179961
[TBL] [Abstract][Full Text] [Related]
2. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.
Karantanos T; Teodorescu P; Arvanitis M; Perkins B; Jain T; DeZern AE; Dalton WB; Christodoulou I; Paun BC; Varadhan R; Esteb C; Rajkhowa T; Bonifant C; Gondek LP; Levis MJ; Yegnasubramanian S; Ghiaur G; Jones RJ
Haematologica; 2023 Jul; 108(7):1886-1899. PubMed ID: 36519323
[TBL] [Abstract][Full Text] [Related]
3. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
Kao HW; Sanada M; Liang DC; Lai CL; Lee EH; Kuo MC; Lin TL; Shih YS; Wu JH; Huang CF; Ogawa S; Shih LY
Neoplasia; 2011 Nov; 13(11):1035-42. PubMed ID: 22131879
[TBL] [Abstract][Full Text] [Related]
4. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia.
Biethahn S; Alves F; Wilde S; Hiddemann W; Spiekermann K
Exp Hematol; 1999 May; 27(5):885-94. PubMed ID: 10340405
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
[TBL] [Abstract][Full Text] [Related]
6. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
7. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome.
Schieber M; Marinaccio C; Bolanos LC; Haffey WD; Greis KD; Starczynowski DT; Crispino JD
Blood Cancer J; 2020 Oct; 10(10):98. PubMed ID: 33024076
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
Geyh S; Rodríguez-Paredes M; Jäger P; Koch A; Bormann F; Gutekunst J; Zilkens C; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
Haematologica; 2018 Sep; 103(9):1462-1471. PubMed ID: 29773599
[TBL] [Abstract][Full Text] [Related]
9. [Transformation of secondary myelodysplastic syndrome to atypical chronic myeloid leukemia in a female patient with acute myeloid leukemia].
Gritsaev SV; Kostroma II; Zapreev IM; Shmidt AV; Tiranova SA; Balashova VA; Martynkevich IS; Chubukina ZV; Semenova NY; Chechetkin AV
Ter Arkh; 2016; 88(7):104-108. PubMed ID: 27459623
[TBL] [Abstract][Full Text] [Related]
10. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
[TBL] [Abstract][Full Text] [Related]
11. The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study.
Ye X; Chen D; Zheng Y; Wu C; Zhu X; Huang J
Hematol Oncol; 2019 Oct; 37(4):438-446. PubMed ID: 31378958
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
Dill V; Kauschinger J; Hauch RT; Buschhorn L; Odinius TO; Müller-Thomas C; Mishra R; Kyncl MC; Schmidt B; Prodinger PM; Hempel D; Bellos F; Höllein A; Kern W; Haferlach T; Slotta-Huspenina J; Bassermann F; Peschel C; Götze KS; Waizenegger IC; Höckendorf U; Jost PJ; Jilg S
Eur J Haematol; 2020 Feb; 104(2):125-137. PubMed ID: 31758597
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
15. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
Chen X; Othus M; Wood BL; Walter RB; Becker PS; Percival ME; Abkowitz JL; Appelbaum FR; Estey EH
Leuk Lymphoma; 2021 May; 62(5):1226-1233. PubMed ID: 33345655
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
Dan C; Chi J; Wang L
Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
Ohanian M; Bueso-Ramos C; Ok CY; Lin P; Patel K; Alattar ML; Khoury JD; Rozovski U; Estrov Z; Huh YO; Cortes J; Abruzzo LV
Cancer Genet; 2015 Nov; 208(11):571-4. PubMed ID: 26382622
[TBL] [Abstract][Full Text] [Related]
19. The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.
Czibere A; Prall WC; Zerbini LF; Grall F; Craigie EC; Ulrich SD; Giagounidis AA; Haas R; Libermann TA; Aivado M
Cell Cycle; 2005 Jun; 4(6):812-7. PubMed ID: 15970671
[TBL] [Abstract][Full Text] [Related]
20. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
